
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **IGKV1-12, IGKV1-17, IGLL5, IGLV3-1, IGHG1, IGHG2, IGHG3, IGHG4, IGHM, IGKC, IGLC2**: These are immunoglobulin (Ig) genes, which are critical components of antibodies. They are involved in antigen recognition and are typically expressed in B cells and plasma cells.<br>- **JCHAIN**: This gene encodes the joining chain of multimeric IgA and IgM, which is important for the polymerization of these immunoglobulins, a characteristic of plasma cells.<br>- **CD79A**: Part of the B-cell receptor complex, essential for B-cell development and signaling.<br>- **MZB1**: A chaperone protein involved in immunoglobulin folding and assembly, often found in plasma cells.<br>- **POU2AF1**: A transcriptional coactivator involved in B-cell development.<br>- **FCRL5, TNFRSF17 (BCMA), SLAMF7**: These are surface markers associated with B cells and plasma cells, with TNFRSF17 being a marker for plasma cells.<br>- **CD38**: A surface glycoprotein highly expressed on plasma cells.<br>- **ST6GAL1**: An enzyme involved in the sialylation of glycoproteins, often upregulated in plasma cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **Plasma Cell Markers**: IGHG1, IGHG2, IGHG3, IGHG4, IGHM, JCHAIN, MZB1, CD38, TNFRSF17, SLAMF7.<br>- **B Cell Markers**: CD79A, POU2AF1, FCRL5.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Cell Atlas, PanglaoDB, and literature on scRNA-seq of breast cancer tissues, the expression of immunoglobulin genes, CD38, and TNFRSF17 strongly suggests a plasma cell identity. These markers are well-documented in the context of plasma cells, especially in the tumor microenvironment.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Given the high expression of immunoglobulin genes, CD38, and TNFRSF17, the most probable general cell type is a **Plasma Cell**. Plasma cells are terminally differentiated B cells that produce antibodies and are often found in the tumor microenvironment, including breast cancer tissues.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Mature Plasma Cells**: Characterized by high expression of immunoglobulin genes, CD38, and TNFRSF17.<br>2. **Memory B Cells transitioning to Plasma Cells**: May express some plasma cell markers but also retain B cell markers like CD79A.<br>3. **Plasmablasts**: An intermediate stage between B cells and fully differentiated plasma cells, potentially expressing a mix of B cell and plasma cell markers.<br><br>The most likely subtype based on the markers is **Mature Plasma Cells**, given the high expression of immunoglobulin genes and plasma cell-specific markers like CD38 and TNFRSF17.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of plasma cells. The high expression of immunoglobulin genes, along with key plasma cell markers such as CD38 and TNFRSF17, supports this annotation. The most probable sub cell type within this cluster is mature plasma cells, which are known for their role in antibody production and presence in the tumor microenvironment.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. The markers listed in the annotation result, such as IGHG1, IGHG2, IGHG3, IGHG4, IGHM, JCHAIN, MZB1, CD38, TNFRSF17, and SLAMF7, are indeed present in the provided marker list and are well-known markers for plasma cells. The analysis correctly identifies the cell type as plasma cells, with a strong emphasis on mature plasma cells, which is supported by the high expression of immunoglobulin genes and plasma cell-specific markers like CD38 and TNFRSF17.<br><br>The annotation also considers the possibility of mixed cell types, such as memory B cells transitioning to plasma cells and plasmablasts, which is appropriate given the presence of some B cell markers like CD79A and POU2AF1. However, the dominant expression of plasma cell markers justifies the primary annotation as mature plasma cells.<br><br>Overall, the annotation is well-supported by the marker list and aligns with known databases and literature on plasma cells in the context of breast cancer tissue.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Plasma Cell</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Mature Plasma Cells</li><li>Memory B Cells transitioning to Plasma Cells</li><li>Plasmablasts</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">95</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset derived from human breast cancer tissue are generally well-executed and scientifically accurate. The analysis correctly identifies the main cell type as plasma cells, which is supported by the high expression of immunoglobulin genes (e.g., IGHG1, IGHG2, IGHG3, IGHG4, IGHM) and plasma cell-specific markers like CD38 and TNFRSF17. These markers are indeed characteristic of plasma cells, particularly mature plasma cells, which aligns with the annotation.<br><br>The annotation process demonstrates a balanced consideration of multiple markers. It does not overly focus on a single marker but rather integrates a range of markers to support the identification of plasma cells. The inclusion of markers such as CD79A and POU2AF1, which are associated with B cells, shows an understanding of the potential presence of mixed cell types, such as memory B cells transitioning to plasma cells and plasmablasts. This consideration adds depth to the analysis and acknowledges the complexity of the tumor microenvironment.<br><br>The annotation also effectively captures the general picture of the cell populations present in the dataset. By identifying mature plasma cells as the primary sub cell type, the analysis aligns with known literature and databases regarding the role of plasma cells in breast cancer tissues. The consideration of potential mixed cell types further enhances the comprehensiveness of the annotation.<br><br>One potential area for improvement could be a more explicit discussion of the rank and relative importance of the markers, as markers appearing earlier in the list may carry more weight. However, the overall analysis remains robust and well-supported by the data.<br><br>In summary, the annotation is scientifically sound, well-balanced, and provides a comprehensive view of the cell types present in the dataset. There are no obvious misclassifications or oversights, and the analysis is consistent with known biological knowledge.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    